Recombinant human interleukin-6 (IL-6) has previously been shown to increase platelet counts in mice and primates. To elucidate the mechanisms underlying this phenomenon, serial analyses were performed on megakaryocytes obtained from rhesus monkeys treated for 8 days with 30 pg/kg/d of recombinant human IL-6. Platelet counts increased to a maximum of 7.8 x 105/pL with biphasic peaks on days 7 and 12 without significant changes in platelet volumes. Large increases in DNA content were seen by two-color flow cytometry and digital image analysis. Ploidy distribution underwent a significant shift between study days 3 and 11 (P < .0001) with large increases in the frequency of 64N and 128N megakaryocytes. The modal ploidy increased from the normal 16N to 64N. Megakaryocyte size, as measured by 0 DATE, STUDIES on the regulatory mechanisms T underlying megakaryocyte development and platelet production have largely been performed either in rodents by manipulating their circulating platelet massLz2 or in vitro with the use of murine and human culture s y s t e m~.~,~ From this mixed approach it has been concluded that thrombocytopoiesis is probably preceded by at least two independently regulated stages of megakaryocyte development: an early proliferative phase, as detected by colony formation in vitro: and a later maturational phase when megakaryocytes increase in size and ploidy.6 Because it has not yet been possible to observe thrombocytopoiesis in vitro, stimulation of platelet production has been assessed in animals by measuring selenomethionine incorporation into newly released platelets.' Recent evidence obtained by radioisotope labeling in guinea pigs suggests that there may be two separable phases of megakaryocyte maturation before platelets are released, a phase of increased protein synthesis followed by a phase of cytoplasmic reorganization.8 Ultrastructural data showing an augmentation in rough endoplasmic reticulum and an increase in the organelle-deficient peripheral zone of megakaryocytes, obtained from rodents 48 hours after experimentally induced thrombocytopenia: seem to support the concept of cytoplasmic reorganization before increased platelet release.
T underlying megakaryocyte development and platelet production have largely been performed either in rodents by manipulating their circulating platelet massLz2 or in vitro with the use of murine and human culture s y s t e m~.~,~ From this mixed approach it has been concluded that thrombocytopoiesis is probably preceded by at least two independently regulated stages of megakaryocyte development: an early proliferative phase, as detected by colony formation in vitro: and a later maturational phase when megakaryocytes increase in size and ploidy. 6 Because it has not yet been possible to observe thrombocytopoiesis in vitro, stimulation of platelet production has been assessed in animals by measuring selenomethionine incorporation into newly released platelets.' Recent evidence obtained by radioisotope labeling in guinea pigs suggests that there may be two separable phases of megakaryocyte maturation before platelets are released, a phase of increased protein synthesis followed by a phase of cytoplasmic reorganization.8 Ultrastructural data showing an augmentation in rough endoplasmic reticulum and an increase in the organelle-deficient peripheral zone of megakaryocytes, obtained from rodents 48 hours after experimentally induced thrombocytopenia: seem to support the concept of cytoplasmic reorganization before increased platelet release.
The advent of recombinant cytokines now provides an opportunity to examine megakaryocyte development and thrombocytopoiesis in vivo without prior alteration of the platelet mass. In this regard, it has already been shown that the administration of recombinant human interleukin-6 (rhIL-6) to mice'o311 and to monkeys" results in elevated peripheral blood platelet counts and that this is accompanied by an increase in the size of their Nonhuman primates are particularly advantageous for such studies because they generally have clinical growth factor responses comparable with those of humans, and primate size permits serial bone marrow analyses on the same animal. In the present study, the sequential effects of rhIL-6 on megakaryocyte maturation and platelet production were evaluated in rhesus monkeys. Our results, based on careful ultrastructural analyses in conjunction with determinations of other parameters of megakaryocyte develarea, was increased 2-to 2.7-fold. On day 3, multiple megakaryocytes were seen in endomitosis, along with an abundance of young cells with wide, organelle-free peripheral zones. The giant megakaryocytes seen on days 5 to 7 exhibited marked membrane hyperplasia that occupied much of the cell. Emperipolesis occurred frequently, as did megakaryocyte cell death. No giant platelets were seen. We conclude that IL-6 significantly alters the process of megakaryocyte maturation and thrombocytopoiesis, and that these effects, at least in the doses of IL-6 administered, should not be equated with the physiologic mechanisms operative during accelerated platelet production. This is a US government work. There are no restrictions on its use. opment and platelet production, suggest that the effects of IL-6 administration may differ significantly from the physiologic responses that occur when the demand for platelet production is increased. Because the clinical use of this cytokine is under consideration and its physiologic relationship with thrombopoietin is as yet undefined, these observations may have important implications. monkeys were treated with 30 pgikgld rhIL-6 in two divided doses subcutaneously on study days 1 through 8. Two control monkeys received 0.2 mL saline subcutaneously twice daily for 8 days.
MATERIALS AND METHODS

Animals
Clinical side effects. IL-&treated monkeys lost between 5% and 10% of their body weight during the study, whereas saline-treated control monkeys did not.
Peripheral blood samples were obtained pretreatment (study day 1) and on days 3,5, 7,9,10,11,12,15,17,19, and 22. Complete blood counts, including platelet counts and mean platelet volume, were enumerated on a Sysmex automated analyzer (Baxter Scientific Products, McGaw Park, IL) on samples collected in K, EDTA vacutainers and analyzed 2 to 4 hours postvenipuncture. Bone marrow aspirates were obtained pretreatment (study day 1) and on days 3,5,7,9,10, 11,12,15, and 22. On study days when treatment was administered, all samples were obtained before the injections. Total blood loss during the study for each monkey was approximately 10 mL/kg. Approximately 1 mL of bone marrow was aspirated directly into supplemented CATCH buffer containing 5% fetal calf serum, prostaglandin E, (1.0 pg/mL), and DNAase I (30 U/mL; Sigma Chemical Co, St Louis, MO). An aliquot was removed and fixed in 3% glutaraldehyde for electron microscopy. The remainder was layered over a discontinuous isotonic Percoll (Pharmacia, Uppsala, Sweden) gradient of density 1.058 g/mL and cells were collected from the interface and top of the gradient. Nucleated marrow cell counts were enumerated on a Coulter Counter ZM (Coulter Electronics, Hialeah, FL).
Cells were processed and analyzed as previously described." Briefly, cells were labeled with a saturating concentration of a fluoresceinated mouse monoclonal antibody (MoAb) (CD,41) directed against human platelet glycoprotein IIb/IIIa (AMAC, Westbrook, MA). Control cells were labeled with a fluorescein-conjugated mouse isotype (IgG1) control (Becton Dickinson, Mountain View, CA). Cells were permeabilized as described by Corash et all4 with 0.5% Tween 20, followed by the addition of 0.5% Tween 20 in 1% paraformaldehyde. DNA was labeled using propidium iodide (50 pg/mL; Sigma). RNAase (50 pg/mL bovine pancreas; Sigma) was added 30 minutes before analysis. From 0.5 to 2 x lo6 cells per bone marrow sample were analyzed at a flow rate of 1,000 to 2,OWisecond on a FACScan (Becton Dickinson). Data were analyzed using the Consort 30 program (Becton Dickinson). Megakaryocytes were selected by excluding 99% of the control cells greater than 4N.I' DNA distributions for megakaryocytes 2 2N were measured; however, DNA ploidy distributions were analyzed for megakaryocytes 2 8N, because small changes in the positioning of the green gate can significantly alter the proportions of the 2N and 4N pop~lations.'~.~~ Megakaryocyte area and DNA content were determined by digital image analysis as previously described.13 Cells were stained as described for flow cytometry. After fixation with 1% paraformaldehyde, 0.2% glutaraldehyde was added to the cell suspension just before microscopy. Wetmounted cells were examined using a 450-to 490-nm barrier filter and a 40X Plan Neofluar objective on a Zeiss Aziovert inverted microscope (Carl Zeiss, Inc, Thornwood, NY) equipped with epifluorescence. Emitted fluorescence was transmitted to a video camera and IM 3000 digital image analysis system (Analytical Imaging Concepts, Irvine, CA) containing 256 gray levels for pixel discrimination. Megakaryocytes were identified by cytoplasmic green fluorescence, and images of between 60 and 100 megakaryocytes were obtained per bone marrow sample. Total nuclear gray values corresponding to the fluorescent intensity of the propidium iodide-stained DNA and megakaryocyte areas reported in micrometers squared were determined. Total nuclear gray values determined in arbitrary units are a product of nuclear area and the average density of pixels within a delineated area. Nuclear DNA Peripheral blood and bone marrow examination.
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thresholds and peak levels were kept constant from sample to sample.
Total nuclear gray values were plotted on a log base 2 scale, and ploidy groupings were determined hy natural breaks in the distributions. These groupings were confirmed by testing for normality using the Shapiro-Wilk statistic." Approximately a twofold difference in the mean total nuclear gray values of the ploidy groups was obtained. The modal ploidy class was assigned to the closest approximation of a multiple of a mean 2N diploid cell DNA value, and in each case the modal ploidy class correlated with FACScanderived data.
Cells were fixed in 3% glutaraldehyde. Dehydration and embedding for thin sections were performed as previously described." Thin sections stained with uranyl acetate and lead citrate were examined in a Siemens Elmskop I electron microscope at original magnifications from 1,700 to 15,OOO.
Statistical analysu. The observed ploidy distributions after treatment with IL-6 or saline were compared with the expected ploidy distributions if no change with treatment had occurred using the xz test for goodness of The Student's t-test was used to compare posttreatment mean total nuclear gray values and megakaryocyte areas with pretreatment values." Results are reported as statistically significant if P 5 .05.
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RESULTS
As had been observed by others, we found that the administration of rhIL-6 to primates resulted in increases in platelet counts. After an initial small decrease on day 3, platelet counts began to increase on day 5 (Fig 1) . Both monkeys demonstrated biphasic peaks, monkey A on days 7 and 12 and monkey B on days 7 and 10, with a maximum increase from 5.4 X 105/pL to 7.8 x 105/pL from pretreatment platelet counts of 3.9 x 105/pL and 4.0 x 105/pL. Despite the large increases in platelet counts, no change in mean platelet volume occurred during the study (range, 9 to 11 fL in both IL-6-and saline-treated animals). Giant platelets, ie, platelets that are composed of more than one platelet field" and that are usually seen with compensatory thrombocytopoiesis, were not found in this study.
Effect of IL-6 on platelets. Effect of ZL-6 on megakaryocyte DNA content. Megakaryocyte ploidy was assessed in bone marrow specimens of rhIL-&treated animals and saline-treated controls by twocolor flow cytometry. It became immediately apparent that IL-6 elicited large increases in the proportions of high ploidy 64N and 128N megakaryocytes. In bone marrow specimens obtained from normal rhesus monkeys, megakaryocytes with a DNA content of 128N or greater are not seen in significant numbers." As shown in Fig 2, ploidy distributions were increased significantly from days 3 through 11 (P < .0001) in monkey A and from days 3 through 12 (P < .0001) in monkey B. Larger changes in ploidy distributions were seen in monkey A. Serial DNA histograms show the increase from the normal 16N modal ploidy to a modal ploidy of 64N on days 5 through 10 and a return to 16N beginning on study day 12 in IL-&treated monkeys (Fig 3) . The highest frequency of megakaryocytes with a DNA content of 64N and 128N was found on day 5. Higher ploidy megakaryocytes began to gradually decrease between days 7 and 10. By day 12,128N megakaryocytes were no longer apparent. Saline-treated controls did not demonstrate sig- nificant changes in ploidy distributions at any time during the study. The increase in DNA content after IL-6 administration was confirmed by digital image analysis. Total nuclear gray values, a measure of propidium iodide-stained DNA intensity, were significantly increased between days 3 and 11 (P < .0001) (Fig 4) . As seen with flow cytometry, the megakaryocytes of monkey A increased their DNA content more than those of monkey B.
rhIL-6 administration resulted in a 2-to 2.7-fold increase in mean megakaryocyte area ( Fig  4B) . These increases parallelled the increases in DNA content. Both monkeys had significantly larger megakaryocytes on days 3 through 11 compared with their pretreatment size (P < .0001). On day 15,l week after discontinuation of IL-6, megakaryocyte size was statistically smaller than normal, but returned to normal by day 22.
In day 3 samples, the increase in size of the cells seen by digital image analysis was not particularly noteworthy on electron microscopy of thin sections. However, even a cursory survey showed a striking number of endomitotic figures among recognizable megakaryocytes. Although the embedding techniques used for electron microscopy may cause an uneven distribution of cell types that precludes precise quantitation, six cells in the process of endomitosis were seen among 53 megakaryocytes studied ultrastructurally (Fig 5) . This result came as a surprise because mitoses are rarely seen in full-sized polyploid megakaryocytes of control specimens. They are also rare A I L among differentiated platelet-producing cells in the marrow of patients with reactive thrombocytosis. In addition to increased mitotic figures, many megakaryocytes in day 3 specimens were sparsely granulated, had not developed platelet fields, and exhibited a wide organelle-free peripheral zone (Fig 5A) . This zone was replete with ribosomes and profiles of membranes that formed flattened cisternae that were oriented, for the most part, parallel to the plasma membrane (Fig 5B) . To our knowledge, megakaryocytes with this type of morphology have not been previously described.
In the samples from days 5 through 9, the enormous size of the cells required original electron microscopic magnifications as low as ~1 , 0 0 0 if the entire cell was to be photographed in one field. However, the most striking feature at this time was the hyperplasia of cytoplasmic membranes, which, to some extent, may have accounted for the marked increase in size of the cells. Compacted stacks of membranes appeared to occupy as much of the cytoplasm as did areas containing organelles (Fig 6) . The peripheral zones had become very narrow, if they existed at all. Evidence of megakaryocyte fragmentation was often seen. Most cells exhibited processes that extended from 1 pm to 3 pm from the surface membrane. In some cells these processes had folded on themselves and invaginated the plasma membrane, giving rise to inclusions resembling those we have reported elsewhere.'' However, whether these internal processes had actually remained in continuity with the plasma membrane would have to be established by tracer studies. A large increase in the number of centrioles was also seen. As is the case during increased megakaryocytosis caused by a variety of stimuli, emperipolesis of leukocytes was conspicuous. Platelets adjacent to fragmenting cells were relatively small (Fig 7) in contrast to the giant forms of megakaryocyte fragments normally seen during accelerated thrombocytopoiesis. In addition, there 3'0 500 -1 3 5 7 9 11 13 15 17 19 21 Effect of IL-6 on (A) mean total nuclear gray values (arbitrary density units) and (6) megakaryocyte area (pm') from treated monkeys are shown. Data were obtained by digital imaging microscopy as described in Materials and Methods. Mean total nuclear gray is a reflection of total nuclear DNA content. Mean total nuclear gray values were significantly different from pretreatment values on days 3 through 11 for monkeys A and 6 (P < .0001). On days 15 and 22, total nuclear gray values were not significantly different from pretreatment values. Mean megakaryocyte area was significantly increased from pretreatment on days 3 t o 11 in monkeys A and 6 (P < 0.0001) and decreased on day 15 in monkeys A and B (P < .01). On study day 22, mean megakaryo- was cvidcncc of mcgakaryocytc dcath, with morphologic charactcristics not prcviously rcportcd. Normally. aftcr platclcts arc shcd, thc nuclcus rcmains intact and is surroundcd by a thin rim of cytoplasm containing a small Golgi apparatus and a fcw organcllcs." In thc IL-6-trcatcd animals, cffctc mcgakaryocytcs wcrc sccn that had not shcd thcir cytoplasm. Instcad, thc cytoplasmic architccturc had hccomc disorganizcd and thc plasma mcmhranc was ill dcfincd, as would hc sccn aftcr osmotic lysis. Thc nuclcus was swollcn with loss of distinction hctwccn thc condcnscd hctcrochromatin and thc morc looscly asscmhlcd cuchromatin. Thcrc was considcrahlc scparation of thc nuclcar lamina (Fig X) . In somc instanccs. thc appcarancc of thcsc cclls was rcminisccnt of cclls in thc proccss of apoptosis, whilc in othcrs thc morphologic critcria by which this proccss is dcfincd wcrc not met."." Bccausc no structural ahnormalitics wcrc sccn in othcr marrow cclls that wcrc in closc apposition to such mcgakaryocytcs. thc pssihility that mcgakaryocytc damagc had hccn due to poor prcscrvation was rulcd out.
Day of Study
By day 12. ic. 4 days aftcr tcrmination of IL-6 administration, cclls wcrc indistinguishahlc from thosc of control animals.
DISCUSSION
1L-6 is a cytokinc with known plciotropic cffccts on hcmatopoicsis as wcll as on thc immunc systcm and on acutc-phasc reactants.",-'" Currcntly, thc cxtcnt of its in vivo rolc as wcll as thc potcntial for its clinical usc arc not fully understood. Bccausc in vivo IL-6 has platclct enhancing effcctsl" I: and. in vitro. it promotcs mcgakaryocytc maturation and colony formation,'7 IL-6 has bccn compared with thrombopoietin":' and its therapeutic uscfulncss is bcing considcrcd. Thc prcscnt study was designed to analyze the in vivo changes in mcgakaryocytc dcvclopmcnt and platclct formation induced by IL-6. Thc data suggest that, dcspitc somc similaritics. thc IL-6stimulatcd proccss of mcgakaryocytc dcvclopmcnt that lcads to incrcascs in platclct counts, at lcast at thc dosc cxamincd, is markedly difTcrcnt from that occurring physiologically in rcsponsc to incrcascd platclct dcmand.
As has bccn obscrvcd by othcrs,"l."~'n thc prcscnt study also showcd that rhlL-6 administration rcsultcd in significant incrcascs in platelet counts, mcgakaryocytc DNA content, and mcgakaryocytc sizc. Intcrcstingly, thc markcd incrcasc in mcgakaryocytc ploidy and sizc that occurred 48 hours (study day 3) aftcr IL-6 initiation was associatcd with a dccrcasc in platclct count. At this timc, numcrous mitotic figures wcrc prcscnt in full-sized mcgakaryocytcs and thcrc was a markcd incrcasc in immaturc cclls. ic, cells that wcrc sparscly granulatcd, wcrc dcvoid of dcmarcatcd platclct ficlds, and had a widc organcllc-frcc pcriphcral zonc (Fig   5) . Thcsc findings sugcst that IL-6 causcs a rclativcly immaturc mcgakaryocytc ccll to incrcasc cndomitosis and, pcrhaps. to dclay platclct production. It is difficult to imaginc that a mcgakaryocytc likc thc onc illustratcd in Fig  SA, which is dcvoid of platclct ficlds and has a vcry widc pcriphcral zonc, would be ready to relcase platclcts. An analogous initial dccreasc in platelet production has also bccn rcportcd by Asano et ill in primatcs administered IL-6," but has not bccn noted with thc administration of thrombocytopenic plasma.-In fact. it is known that platclct production can begin within hours of cxperimcntally induccd thrombocytopenia.-"' By study day 5. 2 days after incrcascs in ploidy and size wcrc notcd, platelct counts began to incrcasc. The unusual stacks of mcmbrancs notcd ultrastructurally may, in part, explain thc immense size that thc IL-(t-stimulatcd megakaryocytcs attained. Although incrcascs in ploidy and sizc arc a wcll recognized phcnomcnon aftcr administration of thromhocytopcnic plasma,"'-' thc magnitudc of thc increase in sizc aftcr IL-6 administration surpasscs by far what occurs in "rcactivc" mcgakaryocytopoicsis. This rcsult could bc attributed to cxccssivc hypcrplasia of mcmbrancs, which sccm to occupy much of thc total ccll volume (Fig 6) . Significant incrcascs in ploidy have bccn noted during sccondary thrombocytosis associatcd with malignancy or inflammatory disordcrs,ll.U but it usually is not apparcnt with compensatory thrombocytosis sccondary to chronic blood loss or iron deficiency." The obscrvation that various malignant and inflammatory disorders, somc of which are associatcd with thrombocytosis, are also accompanicd by incrcascd IL-6 production sccms rclcvant in this regard." It is possihlc that IL-6 plays a physiologic rolc in somc instanccs of sccondary thrombocytosis but not in others. IL-6 administration, unlike compensatory thrombocytosis, did not result in increases in mean platelet volume or in the presence of giant platelets with multiple platelet fields. The lack of any significant effect on mean platelet volume was also noted when IL-6 was administered to mice.'h The absence of giant platelets could be considered a therapeutic shortcoming in view of the clinically observed increased hemostatic cficacy of larger platelets.
In addition to the membrane hyperplasia observed in this study, largc numbers of megakaryocytes that appear to undergo ccll death as a result of IL-6 administration have not hcen noted previously. Morphologically, this process resembled apoptosis, a mechanism of programmed cell death, which, in contrast to pathologic lysis or necrosis, eliminates cells during normal tissue turnover."." Among its roles it has been postulated that programmed cell death counterbalances excessive mitosis." Apoptosis, although not previously reported with IL-6, has been associated with tumor necrosis factor (TNF),'" another inflammatory cytokine with widely overlapping pleiotropic biologic effects. The cachexia exhibited by thc animals in thisstudy. and also seen by others,'' is reminiscent of the biologic effects noted with TNF. However, IL-6 has not been shown to stimulate either TNF or IL-1 production," which suggests that the effccts reported here may be directly related to IL-6 and are part of a homeostatic control mechanism, counterbalancing the megakaryocyte hyperplasia. The unusual biphasic nature of the platclct increase may, perhaps, be explained by the large number of apoptotic megakaryocytes seen on days 7 through 9. It should be recalled that during normal thrombopoiesis megakaryocytes shed most of their cytoplasm, leaving behind an almost denuded nucleus with a well-preserved ultrastructure."
Taken together, the results of the present study demonstrate that the process of increased platelet formation after IL-6 administration to primates should not be equated with physiologic mechanisms that bring about compensatory thrombocytosis. In the final analysis, it must be taken into consideration that the cytokine was administered to animals that had normal baseline platelet counts. The observed megakaryocyte cell death may thus be a physiologic mechanism to control excessive cell development. It remains to be ascertained whether lower doses of IL-6, perhaps in combination with other growth factors, can abrogate some of these unusual features of megakaryocyte development and yet maintain a clinically significant increase in platelet production.* Meanwhilc, this study suggests that there may be important physiologic diffcrenccs between the effects of IL-6 and a lineage-specific thrombopoietin.
'Since submission of this manuscript. experiments on two additional monkeys administered 1L-6 10 pgglkgld for 8 days were performed and the observations were indistinguishable from the results reported here for the higher dose.
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